DK175410B1 - Hundecoronavirus-vaccine - Google Patents
Hundecoronavirus-vaccine Download PDFInfo
- Publication number
- DK175410B1 DK175410B1 DK198803015A DK301588A DK175410B1 DK 175410 B1 DK175410 B1 DK 175410B1 DK 198803015 A DK198803015 A DK 198803015A DK 301588 A DK301588 A DK 301588A DK 175410 B1 DK175410 B1 DK 175410B1
- Authority
- DK
- Denmark
- Prior art keywords
- ccv
- cell
- vaccine
- infection
- cells
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 69
- 241000711506 Canine coronavirus Species 0.000 title claims abstract description 66
- 208000015181 infectious disease Diseases 0.000 claims abstract description 61
- 241000700605 Viruses Species 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 12
- 244000052769 pathogen Species 0.000 claims abstract description 6
- 239000002609 medium Substances 0.000 claims description 24
- 241000282465 Canis Species 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 241000701931 Canine parvovirus Species 0.000 claims description 17
- 238000004113 cell culture Methods 0.000 claims description 17
- 241001465754 Metazoa Species 0.000 claims description 16
- 101710167605 Spike glycoprotein Proteins 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 11
- 230000004224 protection Effects 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 5
- 230000002779 inactivation Effects 0.000 claims description 5
- 230000001681 protective effect Effects 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 239000013553 cell monolayer Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 239000001963 growth medium Substances 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 abstract description 13
- 102000036639 antigens Human genes 0.000 abstract description 13
- 108091007433 antigens Proteins 0.000 abstract description 13
- 229940031348 multivalent vaccine Drugs 0.000 abstract description 4
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 55
- 238000002255 vaccination Methods 0.000 description 26
- 241000282472 Canis lupus familiaris Species 0.000 description 21
- 238000002965 ELISA Methods 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 8
- 208000004232 Enteritis Diseases 0.000 description 7
- 241000282326 Felis catus Species 0.000 description 7
- 230000003472 neutralizing effect Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 208000005577 Gastroenteritis Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 210000003292 kidney cell Anatomy 0.000 description 6
- 241000711573 Coronaviridae Species 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008673 vomiting Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229940030156 cell vaccine Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010048685 Oral infection Diseases 0.000 description 3
- 241000125945 Protoparvovirus Species 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000002480 immunoprotective effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241000004176 Alphacoronavirus Species 0.000 description 2
- 102100034613 Annexin A2 Human genes 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
- 229940031416 bivalent vaccine Drugs 0.000 description 2
- 238000005422 blasting Methods 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000009172 bursting Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940124856 vaccine component Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- OTIXUSNHAKOJBX-UHFFFAOYSA-N 1-(aziridin-1-yl)ethanone Chemical compound CC(=O)N1CC1 OTIXUSNHAKOJBX-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000711443 Bovine coronavirus Species 0.000 description 1
- 241001493036 Canine rotavirus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000003495 Coccidiosis Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010017918 Gastroenteritis viral Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 206010040102 Seroma Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 241000711484 Transmissible gastroenteritis virus Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 229940001442 combination vaccine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 244000309457 enveloped RNA virus Species 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- YYXLGGIKSIZHSF-UHFFFAOYSA-N ethene;furan-2,5-dione Chemical compound C=C.O=C1OC(=O)C=C1 YYXLGGIKSIZHSF-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 208000011140 intestinal infectious disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 210000002729 polyribosome Anatomy 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001141 propulsive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 230000029302 virus maturation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/818—Viral vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/059,437 US4904468A (en) | 1987-06-08 | 1987-06-08 | Canine coronavirus vaccine |
| US5943787 | 1987-06-08 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK301588D0 DK301588D0 (da) | 1988-06-02 |
| DK301588A DK301588A (da) | 1988-12-09 |
| DK175410B1 true DK175410B1 (da) | 2004-09-27 |
Family
ID=22022943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK198803015A DK175410B1 (da) | 1987-06-08 | 1988-06-02 | Hundecoronavirus-vaccine |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US4904468A (no) |
| EP (1) | EP0295057B1 (no) |
| JP (1) | JP2655876B2 (no) |
| KR (1) | KR970000233B1 (no) |
| AT (1) | ATE91902T1 (no) |
| AU (1) | AU612151B2 (no) |
| CA (1) | CA1337267C (no) |
| DE (1) | DE3882599T2 (no) |
| DK (1) | DK175410B1 (no) |
| ES (1) | ES2058283T3 (no) |
| FI (1) | FI87531C (no) |
| HU (1) | HU203984B (no) |
| IE (1) | IE63006B1 (no) |
| IL (1) | IL86635A0 (no) |
| MY (1) | MY103575A (no) |
| NO (1) | NO176004C (no) |
| NZ (1) | NZ224865A (no) |
| PH (1) | PH27018A (no) |
| PT (1) | PT87668B (no) |
| ZA (1) | ZA884040B (no) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5911999A (en) * | 1987-09-28 | 1999-06-15 | Pfizer, Inc. | Vaccine based on TGEV for protection of dogs against canine coronavirus |
| US5232694A (en) * | 1989-05-03 | 1993-08-03 | Akzo N.V. | Canine corona virus vaccine |
| US5672350A (en) * | 1989-08-22 | 1997-09-30 | Veterinary Infectious Disease Organization | Recombinant bovine coronavirus E2 and E3 polypeptides and vaccines |
| US5882649A (en) * | 1990-04-24 | 1999-03-16 | Flustat Pty. Ltd. | Oral vaccine comprising antigen surface-associated with red blood cells |
| KR100186783B1 (ko) * | 1990-04-24 | 1999-05-01 | 게리 왁톤; 산티노 디-지아코모 | 적혈구와 표면-결합된 항원을 포함하는 경구용 백신 |
| US6372224B1 (en) * | 1990-11-14 | 2002-04-16 | Pfizer Inc. | Canine coronavirus S gene and uses therefor |
| US6057436A (en) * | 1990-11-14 | 2000-05-02 | Pfizer Inc. | Canine coronavirus S gene and uses therefor |
| NZ240558A (en) | 1990-11-14 | 1994-11-25 | Smithkline Beecham Corp | Recombinant feline coronavirus s proteins useful in diagnosis and vaccination against feline peritonitis virus disease |
| WO1993023423A1 (en) * | 1992-05-08 | 1993-11-25 | Smithkline Beecham Corporation | Canine coronavirus s gene and uses therefor |
| EP0510773B1 (en) * | 1991-04-25 | 2003-12-17 | Akzo Nobel N.V. | Canine coronavirus subunit vaccine |
| EP0524672A1 (en) * | 1991-06-27 | 1993-01-27 | Duphar International Research B.V | CCV vaccine |
| US20040063093A1 (en) * | 1992-04-08 | 2004-04-01 | Pfizer, Inc. | Recombinant feline coronavirus S proteins |
| US5750112A (en) * | 1993-02-26 | 1998-05-12 | Solvay Animal Health, Inc. | Canine coronavirus vaccine from feline enteric coronavirus |
| PT1780216E (pt) * | 2005-10-26 | 2011-02-03 | Canio Buonavoglia | Coronavírus canino pantrópico |
| US7761389B2 (en) | 2007-08-23 | 2010-07-20 | Gm Global Technology Operations, Inc. | Method for anomaly prediction of battery parasitic load |
| EP2488634A4 (en) * | 2009-10-14 | 2013-04-03 | Univ Oklahoma State | ISOLATION OF A VIRUS RELATED TO DOG PARVOVIRUS 2 IN A WASHBASIN |
| JP5980947B2 (ja) | 2012-11-22 | 2016-08-31 | 旭化成メディカル株式会社 | 高感染価のパルボウイルスの生産方法 |
| CN106290880B (zh) * | 2015-05-27 | 2019-01-04 | 江苏雷森生物科技有限公司 | 一种用于犬冠状病毒的免疫层析用试剂组合物及检测方法 |
| EP3372677B8 (en) | 2015-11-06 | 2019-09-25 | Asahi Kasei Medical Co., Ltd. | Method for producing parvovirus having high infectivity titer and high purity |
| CN110903387A (zh) * | 2019-12-17 | 2020-03-24 | 吉林省纽卓莱生物科技有限责任公司 | 一种犬冠状病毒免疫球蛋白F(ab′)2及其制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4567042A (en) * | 1983-06-15 | 1986-01-28 | American Home Products Corporation | Inactivated canine coronavirus vaccine |
| US4567043A (en) * | 1983-06-15 | 1986-01-28 | American Home Products Corporation (Del.) | Canine corona virus vaccine |
| DE3650289T2 (de) * | 1985-03-29 | 1995-08-10 | British Tech Group | Spike-protein des virus der infektiösen bronchitis. |
-
1987
- 1987-06-08 US US07/059,437 patent/US4904468A/en not_active Expired - Lifetime
-
1988
- 1988-05-31 PH PH36999A patent/PH27018A/en unknown
- 1988-06-01 NZ NZ224865A patent/NZ224865A/en unknown
- 1988-06-02 DK DK198803015A patent/DK175410B1/da not_active IP Right Cessation
- 1988-06-06 IL IL86635A patent/IL86635A0/xx unknown
- 1988-06-07 ZA ZA884040A patent/ZA884040B/xx unknown
- 1988-06-07 DE DE88305190T patent/DE3882599T2/de not_active Expired - Fee Related
- 1988-06-07 PT PT87668A patent/PT87668B/pt not_active IP Right Cessation
- 1988-06-07 CA CA 568758 patent/CA1337267C/en not_active Expired - Fee Related
- 1988-06-07 NO NO882500A patent/NO176004C/no not_active IP Right Cessation
- 1988-06-07 IE IE168988A patent/IE63006B1/en not_active IP Right Cessation
- 1988-06-07 ES ES88305190T patent/ES2058283T3/es not_active Expired - Lifetime
- 1988-06-07 FI FI882689A patent/FI87531C/fi active IP Right Grant
- 1988-06-07 EP EP19880305190 patent/EP0295057B1/en not_active Expired - Lifetime
- 1988-06-07 AT AT88305190T patent/ATE91902T1/de not_active IP Right Cessation
- 1988-06-07 JP JP14035988A patent/JP2655876B2/ja not_active Expired - Fee Related
- 1988-06-08 AU AU17476/88A patent/AU612151B2/en not_active Ceased
- 1988-06-08 HU HU882965A patent/HU203984B/hu not_active IP Right Cessation
- 1988-06-08 MY MYPI88000624A patent/MY103575A/en unknown
- 1988-06-08 KR KR1019880006816A patent/KR970000233B1/ko not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ224865A (en) | 1990-12-21 |
| ZA884040B (en) | 1989-09-27 |
| HUT46858A (en) | 1988-12-28 |
| FI882689A (fi) | 1988-12-09 |
| IE881689L (en) | 1988-12-08 |
| DE3882599D1 (de) | 1993-09-02 |
| FI882689A0 (fi) | 1988-06-07 |
| IE63006B1 (en) | 1995-03-22 |
| AU612151B2 (en) | 1991-07-04 |
| NO882500D0 (no) | 1988-06-07 |
| ATE91902T1 (de) | 1993-08-15 |
| FI87531B (fi) | 1992-10-15 |
| NO176004B (no) | 1994-10-10 |
| CA1337267C (en) | 1995-10-10 |
| FI87531C (fi) | 1993-01-25 |
| EP0295057B1 (en) | 1993-07-28 |
| NO176004C (no) | 1995-01-18 |
| MY103575A (en) | 1993-08-28 |
| JP2655876B2 (ja) | 1997-09-24 |
| DK301588D0 (da) | 1988-06-02 |
| DK301588A (da) | 1988-12-09 |
| US4904468A (en) | 1990-02-27 |
| NO882500L (no) | 1988-12-09 |
| JPS63316739A (ja) | 1988-12-26 |
| IL86635A0 (en) | 1988-11-30 |
| ES2058283T3 (es) | 1994-11-01 |
| EP0295057A3 (en) | 1989-12-27 |
| DE3882599T2 (de) | 1994-02-10 |
| PT87668B (pt) | 1992-09-30 |
| KR970000233B1 (ko) | 1997-01-08 |
| PH27018A (en) | 1993-02-01 |
| EP0295057A2 (en) | 1988-12-14 |
| KR890000105A (ko) | 1989-03-11 |
| AU1747688A (en) | 1988-12-08 |
| HU203984B (en) | 1991-11-28 |
| PT87668A (pt) | 1988-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK175410B1 (da) | Hundecoronavirus-vaccine | |
| Liess et al. | Studies on transplacental transmissibility of a Bovine Virus Diarrhoea (BVD) vaccine virus in cattle 1: II. Inoculation of pregnant cows without detectable neutralizing antibodies to BVD virus 90–229 days before parturition (51st to 190th day of gestation) | |
| Cook et al. | Preliminary antigenic characterization of an avian pneumovirus isolated from commercial turkeys in Colorado, USA | |
| EP0344872B2 (en) | Vaccine composition | |
| DK162421B (da) | Hundeparvovirus-vaccine, fremgangsmaade til fremstilling heraf og virusstamme til brug i vaccinen | |
| US6951650B1 (en) | Antigenic class of avian reoviruses | |
| CA1184115A (en) | Infectious bronchitis vaccines for poultry and process for the preparation of such vaccines | |
| Wu et al. | Antigenic and immunogenic characterization of infectious bronchitis virus strains isolated in China between 1986 and 1995 | |
| CA2116500C (en) | Canine coronavirus vaccine from feline enteric coronavirus | |
| KR100302522B1 (ko) | 고양이장코로나바이러스로부터의개코로나바이러스왁찐 | |
| Mukiibi-Muka et al. | Local and systemic IgA and IgG responses of chicks to avian reoviruses: effects of age of chick, route of infection and virus strain | |
| JP2006503863A (ja) | トリ吸収不良症候群に関与するウイルスを含有するワクチンおよびその投与法 | |
| EP1543113B1 (en) | Chicken astrovirus type 2 | |
| AU721367B2 (en) | Canine coronavirus vaccine from feline enteric coronavirus | |
| Wanzila Usyu Mutinda | Isolation, pathological and immunological characterization of kenyan infectious bursal disease virus strains for vaccine development | |
| Geerligs et al. | An international journal dedicated to avian health | |
| Shazali | Development of an Inactivated Vaccine against Infectious Bursal Disease Virus | |
| MXPA99007134A (en) | Infectious bursitis vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PBP | Patent lapsed |
Country of ref document: DK |